Chart Analysis
PKY Daily Timeframe Chart as of 29 April 2026
Pathkey.AI (ASX: PKY) Acquires Chipforge Semiconductor Design Platform From NTU Singapore — 560M Shares Issued at $0.022 as Clinical Trial AI Company Pivots Into Chip Design
A company that generated A$27,783 in revenue last year (down 93%) is acquiring a pre-revenue AI semiconductor chip design platform for 560 million shares — nearly doubling its share count — at a deemed price of A$0.022 while trading at $0.052. Pathkey.AI has entered a binding agreement to acquire 100% of Singapore-based Chipforge Pte Ltd, which holds an exclusive worldwide licence from Nanyang Technological University for technology that translates high-level chip design intent into verified hardware code using agentic AI. Chipforge has no product, no customers, and no revenue. The stock moved +26.8% to $0.052 on 29 April 2026 after spiking +73% to a 52-week high of $0.071 and reversing 27% from the session peak — the latest in a series of severe intraday fades across this article series.
What Chipforge Is Building — And What It Hasn't Built Yet
Chipforge is developing an AI platform for semiconductor design and verification: engineers describe what they want a chip to do, and the system generates hardware description language (HDL) code, builds verification tests, and progresses the design through synthesis. Verification alone routinely consumes more than half of a chip project's budget and timeline. The platform's roadmap extends toward full ASIC development.
Target markets include defence, aerospace, critical infrastructure, universities, and companies developing custom chips for AI and edge computing. The core technology is licensed exclusively from NTU via Ntuitive Pte Ltd — but that licence carries milestones that must be met to retain exclusivity:
| Milestone | Deadline |
|---|---|
| Raise ≥S$1,000,000 | 2 February 2027 |
| First commercial sale | 2 February 2028 |
| S$1,000,000 cumulative revenue | 2 February 2031 |
Failure to meet any milestone could result in loss of the exclusive licence — the foundation of the entire acquisition thesis. Ntuitive's consent to the change of control is a condition precedent that has not yet been obtained.
The Deal — 92% Dilution Before Performance Rights
| Component | Value |
|---|---|
| Consideration Shares | 560,000,000 at $0.022 deemed price |
| Performance Rights | 150,000,000 (Class A: MVP within 9 months; Class B: binding commercial deal within 12 months) |
| Chipforge Debt Repayment | Up to A$500,000 |
| Capital Raising | None contemplated |
| PKY Cash | A$3.26M (31 March 2026) + ~A$840K expected R&D rebates |
Post-acquisition shares on issue jump from 607 million to 1.17 billion (~92% increase). If all performance rights vest, dilution reaches ~117%. The deemed issue price of $0.022 sits at a 58% discount to the announcement-day close — meaning the Chipforge vendors receive shares valued at less than half the current market price, which is unusual and may reflect the early stage of the technology.
The Pivot Question — Clinical Trials to Chip Design
PKY's existing platform, TrialKey, applies AI to clinical trial design optimisation. The company describes both TrialKey and Chipforge as sharing the same agentic AI architecture (LLMs + neuro-symbolic reasoning). The claimed synergy — that know-how transfers bidirectionally between clinical trial optimisation and semiconductor verification — is conceptual and commercially unvalidated. The competitive landscape includes Synopsys, Cadence, and internal AI tools at major semiconductor companies.
Risks & Considerations
The acquisition combines two pre-revenue platforms (TrialKey: A$27,783 FY2025 revenue; Chipforge: zero revenue) under one ASX-listed entity with A$3.26 million in cash and A$4.1 million in planned expenditure over 12 months. The company states no capital raising is contemplated, but if development costs exceed estimates or R&D rebates are delayed, the runway compresses quickly.
The 27% intraday fade from $0.071 to $0.052 — with the close in the lower third of the session range — indicates the market's initial enthusiasm was sharply tempered by sellers during the session. The stock had already attracted an ASX price and volume query before the announcement, rising from $0.030 to $0.046 on elevated volume in the preceding sessions, suggesting the market was trading on anticipation before full details were disclosed.
Shareholder approval is required at a general meeting expected 15 June 2026. The acquisition is also conditional on Ntuitive consent to the change of control of Chipforge.
Key Dates & Timeline
| Date | Event |
|---|---|
| 29 April 2026 | Binding SPA announced; stock moved +26.8% |
| ~15 June 2026 | General meeting — shareholder vote |
| ~18 June 2026 | Expected completion |
| 9 months post-issue | Class A milestone: MVP demonstration |
| 12 months post-issue | Class B milestone: binding commercial agreement |
| February 2027 | Ntuitive licence milestone: raise S$1M |
| February 2028 | Ntuitive licence milestone: first commercial sale |
Price Data
- Previous Close: $0.041
- Close Price (29 April 2026): $0.052
- Change (29 April 2026): +26.8%
- 52-Week Range: $0.013 – $0.071
Notable Price Levels
-
$0.071 — 52-week high and intraday high, rejected 27% to close at $0.052. The stock gave back nearly half its intraday gains, indicating sellers overwhelmed the initial buying impulse. This level represents the maximum speculative premium assigned on first reaction to Chipforge.
-
$0.052 — announcement-day close in the lower third of the session range. At this price, the Chipforge consideration shares (deemed at $0.022) are immediately in-the-money by 136% — creating potential selling pressure when they become tradeable post-completion.
-
$0.022 — deemed issue price for the 560M consideration shares and the Chipforge vendor cost basis. Also a historical trading zone from Q3 2025. Below this level, the effective deal value to vendors is negative.
-
$0.013 — 52-week low. A return here would reverse both the Chipforge acquisition narrative and the TrialKey platform, pricing PKY at its lowest 12-month valuation.
Summary
Pathkey.AI is acquiring 100% of Singapore-based Chipforge — an AI semiconductor design platform with an exclusive NTU licence, no product, no customers, and no revenue — for 560 million shares and 150 million performance rights, nearly doubling the share count. The stock moved +26.8% to $0.052 on 29 April 2026 after a 27% intraday reversal from the $0.071 session high. The acquisition pivots a clinical trial AI company (A$27,783 FY2025 revenue) into chip design, with the claimed synergy being shared agentic AI architecture. The NTU licence carries commercialisation milestones through 2031 that must be met to retain exclusivity. No capital raising is contemplated against A$3.26 million in cash and A$4.1 million in planned 12-month expenditure. Shareholder approval is required at a general meeting expected 15 June 2026.
This article is for informational purposes only and does not constitute financial advice. Market Flow does not recommend buying or selling any securities. Past performance is not indicative of future results. Readers should conduct their own independent research and consult a licensed financial adviser before making any investment decisions. This content is published in accordance with ASX Market Rules and is not a financial product recommendation.